Publicaciones

Androdias G, Lünemann JD, Maillart E, Amato MP, Audoin B, Bruijstens AL, Bsteh G, Butzkueven H, Ciccarelli O, Cobo-Calvo A, Derfuss T, Di Pauli F, Edan G, Enzinger C, Geraldes R, Granziera C, Hacohen Y, Hartung HP, Hynes S, Inglese M, Kappos L, Kuusisto H, Langer-Gould A, Magyari M, Marignier R, Montalban X, Mycko MP, Nourbakhsh B, Oh J, Oreja-Guevara C, Piehl F, Prosperini L, Sastre-Garriga J, Sellebjerg F, Selmaj K, Siva A, Tallantyre E, van Pesch V, Vukusic S, Weinstock-Guttman B, Zipp F, Tintoré M, Iacobaeus E, Stankoff B. De-escalating and discontinuing disease-modifying therapies in multiple sclerosis. Brain. 2024 Dec 21. PMID: 39707906

Giovannoni G, Boyko A, Correale J, Edan G, Freedman MS, Montalban X, Rammohan K, Stefoski D, Yamout B, Leist T, Aydemir A, Borsi L, Verdun di Cantogno E. Long-term follow-up of patients with a first clinical demyelinating event (clinically isolated syndrome) who received cladribine tablets in CLASSIC-MS: Findings for the ORACLE-MS cohort. Mult Scler. 2024 Dec 17. PMID: 39690897

Brochet B, Solari A, Lechner-Scott J, Piehl F, Langdon D, Hupperts R, Selmaj K, Patti F, Brieva L, Maidal EM, Alexandri N, Smyk A, Nolting A, Montalban X, Kubala Havrdova E. Improvements in quality of life of people with relapsing multiple sclerosis treated with cladribine tablets during the 2-year CLARIFY-MS study: a plain language summary. Neurodegener Dis Manag. 2024 Dec 16. PMID: 39676554

Mongay-Ochoa N, Pareto D, Alberich M, Carbonell-Mirabent P, Valsasina P, Margoni M, Braga N, Vidal-Jordana A, Auger C, Tintore M, Meani A, Gobbi C, Zecca C, Barkhof F, Schoonheim MM, Strijbis EMM, Gallo A, Bisecco A, Ciccarelli O, De Angelis F, Yiannakas MC, Palace J, Matthews L, Gass A, Eisele P, Lukas C, Bellenberg B, Preziosa P, Montalban X, Rocca MA, Filippi M, Rovira À, Sastre-Garriga J, MAGNIMS study group (Magnetic Resonance Imaging in Multiple Sclerosis). Association of the Cervical Canal Area With Disability and Progression in People With Multiple Sclerosis. Neurology. 2025 Jan 14. PMID: 39666921

Comabella M, Hegen H, Villar LM, Rejdak K, Sao-Avilés A, Behrens M, Sastre-Garriga J, Mongay N, Berek K, Martínez-Yelamos S, Pérez-Miralles F, Abdelhak A, Bachhuber F, Tumani H, Lycke J, Carbonell-Mirabent P, Valls-Carbó A, Rosenstein I, Alvarez-Lafuente R, Castillo-Triviño T, Otaegui D, Llufriu S, Blanco Y, Sánchez-López AJ, García-Merino A, Fissolo N, Gutiérrez L, Villacieros-Álvarez J, Monreal E, Wiendl H, Montalban X, Lünemann JD. Increased EBNA1-specific antibody response in primary-progressive multiple sclerosis. J Neurol. 2024 Dec 12. PMID: 39666032

Villacieros-Álvarez J, Lunemann JD, Sepulveda M, Valls-Carbó A, Dinoto A, Fernández V, Vilaseca A, Castillo M, Arrambide G, Bollo L, Espejo C, Llufriu S, Blanco Y, Armangue T, Álvarez Bravo G, Quiroga-Varela A, Ramió Torrentà L, Cobo-Calvo A, Tintore M, Mariotto S, Montalban X, Comabella M. Complement Activation Profiles Predict Clinical Outcomes in Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease. Neurol Neuroimmunol Neuroinflamm. 2025 Jan. PMID: 39661937

Pinteac R, Soriano J, Matute-Blanch C, Lizcano JM, Duarri A, Malhotra S, Eixarch H, López Comellas G, Montalban X, Comabella M. Chitinase 3-like 1 is neurotoxic in multiple sclerosis patient-derived cortical neurons. Clin Transl Med. 2024 Dec. PMID: 39658520

Brownlee WJ, Vidal-Jordana A, Shatila M, Strijbis E, Schoof L, Killestein J, Barkhof F, Bollo L, Rovira A, Sastre-Garriga J, Tintore M, Rocca MA, Esposito F, Azzimonti M, Filippi M, Bodini B, Lazzarotto A, Stankoff B, Montalban X, Toosy AT, Thompson AJ, Ciccarelli O, MAGNIMS Study Group. Towards a Unified Set of Diagnostic Criteria for Multiple Sclerosis. Ann Neurol. 2024 Nov 28. PMID: 39605172

Chuquisana O, Spatola M, Dinoto A, Sepúlveda M, Mariotto S, Tintore M, Montalban X, Comabella M, Lünemann JD. Soluble TREM2 distinguishes neuromyelitis optica spectrum disorder from MOG antibody disease. Brain. 2024 Nov 12. PMID: 39530260

Carvajal R, Rodríguez-Acevedo B, García-Vasco L, Zabalza A, Ariño H, Bollo L, Cabello-Clotet N, Castilló J, Cobo-Calvo Á, Comabella M, Falcó-Roget A, Galán I, García-Sarreón A, Gómez-Estévez I, Granados G, La Puma D, Mato Chain G, Midaglia L, Nieto-García A, Otero-Romero S, Pappolla A, Rodriguez M, Sansano I, Río J, Tagliani P, Tur C, Vidal-Jordana Á, Vilaseca A, Villar A, Sastre-Garriga J, Oreja-Guevara C, Tintoré M, Montalban X, Arrambide G. Secondary organising pneumonia associated to COVID-19 infection in patients with central nervous system inflammatory demyelinating diseases treated with anti-CD20 therapies. Mult Scler. 2024 Dec. PMID: 39520297

Montalban X, Rodriguez-Acevedo B, Nos C, Resina M, Forner M, Wu Y, Chirieac M. SCALA: a randomized phase I trial comparing subcutaneous and intravenous alemtuzumab in patients with progressive multiple sclerosis. Ther Adv Neurol Disord. 2024. PMID: 39513023

Portaccio E, Magyari M, Havrdova EK, Ruet A, Brochet B, Scalfari A, Di Filippo M, Tur C, Montalban X, Amato MP. Multiple sclerosis: emerging epidemiological trends and redefining the clinical course. Lancet Reg Health Eur. 2024 Sep. PMID: 39444703

Montalban X, Vermersch P, Arnold DL, Bar-Or A, Cree BAC, Cross AH, Kubala Havrdova E, Kappos L, Stuve O, Wiendl H, Wolinsky JS, Dahlke F, Le Bolay C, Shen Loo L, Gopalakrishnan S, Hyvert Y, Javor A, Guehring H, Tenenbaum N, Tomic D, evolutionRMS investigators. Safety and efficacy of evobrutinib in relapsing multiple sclerosis (evolutionRMS1 and evolutionRMS2): two multicentre, randomised, double-blind, active-controlled, phase 3 trials. Lancet Neurol. 2024 Nov. PMID: 39307151

Zabalza A, Pappolla A, Comabella M, Montalban X, Malhotra S. MiRNA-based therapeutic potential in multiple sclerosis. Front Immunol. 2024. PMID: 39267760

Lünemann JD, Sao Avilés A, Tintoré M, Midaglia L, Fissolo N, Gutiérrez L, Wiendl H, Montalban X, Comabella M. Cytomegalovirus immune responses are associated with lower serum NfL and disability accumulation risk at multiple sclerosis onset. Mult Scler. 2024 Oct. PMID: 39246021

Monreal E, Fernández-Velasco JI, Álvarez-Lafuente R, Sainz de la Maza S, García-Sánchez MI, Llufriu S, Casanova B, Comabella M, Martínez-Yélamos S, Galimberti D, Ramió-Torrentà L, Martínez-Ginés ML, Aladro Y, Ayuso L, Martínez-Rodríguez JE, Brieva L, Villarrubia N, Eichau S, Zamora J, Rodero-Romero A, Espiño M, Blanco Y, Saiz A, Montalbán X, Tintoré M, Domínguez-Mozo MI, Cuello JP, Romero-Pinel L, Ghezzi L, Pilo de la Fuente B, Pérez-Miralles F, Quiroga-Varela A, Rubio L, Rodríguez-Jorge F, Chico-García JL, Sainz-Amo R, Masjuan J, Costa-Frossard L, Villar LM. Serum biomarkers at disease onset for personalized therapy in multiple sclerosis. Brain. 2024 Dec 3. PMID: 39101570

Sastre-Garriga J, Vidal-Jordana A, Toosy AT, Enzinger C, Granziera C, Frederiksen J, Ciccarelli O, Filippi M, Montalban X, Tintore M, Pareto D, Rovira À, MAGNIMS Study Group. Value of Optic Nerve MRI in Multiple Sclerosis Clinical Management: A MAGNIMS Position Paper and Future Perspectives. Neurology. 2024 Aug 13. PMID: 39018513

Fernández O, Montalbán X, Agüera E, Aladro Y, Alonso A, Arroyo R, Brieva L, Calles C, Costa-Frossard L, Eichau S, García-Domínguez JM, Hernández MA, Landete L, Llaneza M, Llufriu S, Meca-Lallana JE, Meca-Lallana V, Moral E, Prieto JM, Ramió-Torrentà L, Téllez N, Romero-Pinel L, Vilaseca A, Rodríguez-Antigüedad A. [XVI Post-ECTRIMS Meeting: review of the new developments presented at the 2023 ECTRIMS Congress (II)]. Rev Neurol. 2024 Jul 16. PMID: 38976584

Zaratin P, Samadzadeh S, Seferoğlu M, Ricigliano V, Dos Santos Silva J, Tunc A, Brichetto G, Coetzee T, Helme A, Khan U, McBurney R, Peryer G, Weiland H, Baneke P, Battaglia MA, Block V, Capezzuto L, Carment L, Cortesi PA, Cutter G, Leocani L, Hartung HP, Hillert J, Hobart J, Immonen K, Kamudoni P, Middleton R, Moghames P, Montalban X, Peeters L, Sormani MP, van Tonder S, White A, Comi G, Vermersch P. The global patient-reported outcomes for multiple sclerosis initiative: bridging the gap between clinical research and care - updates at the 2023 plenary event. Front Neurol. 2024. PMID: 38974689

Fernández O, Montalbán X, Agüera E, Aladro Y, Alonso A, Arroyo R, Brieva L, Calles C, Costa-Frossard L, Eichau S, García-Domínguez JM, Hernández MA, Landete L, Llaneza M, Llufriu S, Meca-Lallana JE, Meca-Lallana V, Moral E, Prieto JM, Ramió-Torrentà L, Téllez N, Romero-Pinel L, Vilaseca A, Rodríguez-Antigüedad A. [XVI Post-ECTRIMS Meeting: review of the new developments presented at the 2023 ECTRIMS Congress (I)]. Rev Neurol. 2024 Jul 1. PMID: 38934946

Dema M, Eixarch H, Castillo M, Montalban X, Espejo C. IL-6 Inhibition as a Therapeutic Target in Aged Experimental Autoimmune Encephalomyelitis. Int J Mol Sci. 2024 Jun 19. PMID: 38928437

Lunemann JD, Hegen H, Villar LM, Rejdak K, Sao-Aviles A, Carbonell-Mirabent P, Sastre-Garriga J, Mongay-Ochoa N, Berek K, Martínez-Yélamos S, Pérez-Miralles F, Abdelhak A, Bachhuber F, Tumani H, Lycke JN, Rosenstein I, Alvarez-Lafuente R, Castillo-Trivino T, Otaegui D, Llufriu S, Blanco Y, Sánchez López AJ, Garcia Merino JA, Fissolo N, Gutierrez L, Villacieros-Álvarez J, Monreal E, Valls-Carbó A, Wiendl H, Montalban X, Comabella M. Association of Complement Factors With Disability Progression in Primary Progressive Multiple Sclerosis. Neurol Neuroimmunol Neuroinflamm. 2024 Jul. PMID: 38912898

Collorone S, Coll L, Lorenzi M, Lladó X, Sastre-Garriga J, Tintoré M, Montalban X, Rovira À, Pareto D, Tur C. Artificial intelligence applied to MRI data to tackle key challenges in multiple sclerosis. Mult Scler. 2024 Jun. PMID: 38738527

Kappos L, Edan G, Freedman MS, Hartung HP, Montalbán X, Barkhof F, Koelbach R, MacManus DG, Wicklein EM, BENEFIT and BENEFIT 15 Study Groups. Long-term clinical outcomes in patients with CIS treated with interferon beta-1b: results from the 15-year follow up of the BENEFIT trial. J Neurol. 2024 Jul. PMID: 38730097

Fox RJ, Cree BAC, de Sèze J, Gold R, Hartung HP, Jeffery D, Kappos L, Montalban X, Weinstock-Guttman B, Singh CM, Altincatal A, Belviso N, Avila RL, Ho PR, Su R, Engle R, Sangurdekar D, de Moor C, Fisher E, Kieseier BC, Rudick RA. Temporal Relationship Between Serum Neurofilament Light Chain and Radiologic Disease Activity in Patients With Multiple Sclerosis. Neurology. 2024 May 14. PMID: 38648580

Carvajal R, Zabalza A, Carbonell-Mirabent P, Martínez-Gómez X, Esperalba J, Pappolla A, Rando A, Cobo-Calvo A, Tur C, Rodriguez M, Río J, Comabella M, Castilló J, Rodrigo-Pendás JÁ, Braga N, Mongay-Ochoa N, Guío-Sánchez C, Vidal-Jordana Á, Arrambide G, Rodríguez-Acevedo B, Midaglia L, Borras-Bermejo B, Galán I, Sastre-Garriga J, Montalban X, Otero-Romero S, Tintoré M. Vaccine Safety and Immunogenicity in Patients With Multiple Sclerosis Treated With Natalizumab. JAMA Netw Open. 2024 Apr 1. PMID: 38607624

Malhotra S, Fissolo N, Rodríguez-Rivera C, Monreal E, Montpeyo M, Urcelay E, Triviño JC, Pérez-García MJ, Segura MF, Pappolla A, Río J, Vilaseca A, Fernández Velasco JI, Miguez A, Goicoechea C, Martinez-Vicente M, Villar LM, Montalban X, Comabella M. Clusterin deficiency is associated with a lack of response to teriflunomide in multiple sclerosis. Clin Transl Med. 2024 Apr. PMID: 38591764

Pappolla A, Auger C, Sao-Aviles A, Tur C, Rodriguez-Barranco M, Cobo-Calvo Á, Mongay-Ochoa N, Rodríguez-Acevedo B, Zabalza A, Midaglia L, Carbonell-Mirabent P, Carvajal R, Castilló-Justribó J, Braga N, Bollo L, Vidal-Jordana A, Arrambide G, Nos C, Salerno A, Galán I, Comabella M, Sastre-Garriga J, Tintoré M, Rovira A, Montalban X, Río J. Prediction of disease activity and treatment failure in relapsing-remitting MS patients initiating daily oral DMTs. Mult Scler. 2024 Jun. PMID: 38551315

Giramé-Rizzo L, de Gordoa ES, Vilaseca A, Auger C, Montalban X. An emerging etiology of spinal cord injury resembling neuromyelitis optica spectrum disorder. Neurol Sci. 2024 Aug. PMID: 38483675

Bollo L, Arrambide G, Cobo-Calvo A, Alvarez JV, Alberich M, Cabello S, Castilló J, Galan I, Midaglia LS, Acevedo BR, Zabalza A, Pappolla A, Mongay Ochoa N, Tintore M, Rio J, Comabella M, Tur C, Auger C, Sastre-Garriga J, Rovira A, Montalban X, Pareto D, Vidal-Jordana A. Trans-Synaptic Degeneration in the Visual Pathway in Patients With Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease. Neurology. 2024 Apr 9. PMID: 38447105

Montalban X, Piasecka-Stryczynska K, Kuhle J, Benkert P, Arnold DL, Weber MS, Seitzinger A, Guehring H, Shaw J, Tomic D, Hyvert Y, Harlow DE, Dyroff M, Wolinsky JS. Efficacy and safety results after >3.5 years of treatment with the Bruton's tyrosine kinase inhibitor evobrutinib in relapsing multiple sclerosis: Long-term follow-up of a Phase II randomised clinical trial with a cerebrospinal fluid sub-study. Mult Scler. 2024 Apr. PMID: 38436271

Arnold DL, Elliott C, Martin EC, Hyvert Y, Tomic D, Montalban X. Effect of Evobrutinib on Slowly Expanding Lesion Volume in Relapsing Multiple Sclerosis: A Post Hoc Analysis of a Phase 2 Trial. Neurology. 2024 Mar 12. PMID: 38335474

Braga N, Pareto D, Mongay-Ochoa N, Rodriguez B, Appriou C, Alberich M, Cabello S, Vidal-Jordana A, Tintore M, Montalban X, Rovira À, Sastre-Garriga J. Optic chiasm manual and automated measurements in sub-acute optic neuritis with OCT and MRI correlations. Eur J Radiol. 2024 Mar. PMID: 38290202

Vidal-Jordana A, Sastre-Garriga J, Tintoré M, Rovira À, Montalban X. Optic nerve topography in multiple sclerosis diagnostic criteria: Existing knowledge and future directions. Mult Scler. 2024 Feb. PMID: 38243584

Oh J, Capezzuto L, Kriara L, Schjodt-Eriksen J, van Beek J, Bernasconi C, Montalban X, Butzkueven H, Kappos L, Giovannoni G, Bove R, Julian L, Baker M, Gossens C, Lindemann M. Use of smartphone-based remote assessments of multiple sclerosis in Floodlight Open, a global, prospective, open-access study. Sci Rep. 2024 Jan 2. PMID: 38168498

Vidal-Jordana A, Rovira A, Calderon W, Arrambide G, Castilló J, Moncho D, Rahnama K, Collorone S, Toosy AT, Ciccarelli O, Papadopoulou A, Cerdá-Fuertes N, Lieb JM, Ruggieri S, Tortorella C, Gasperini C, Bisecco A, Capuano R, Gallo A, De Barros A, Salerno A, Auger C, Sastre-Garriga J, Tintore M, Montalban X. Adding the Optic Nerve in Multiple Sclerosis Diagnostic Criteria: A Longitudinal, Prospective, Multicenter Study. Neurology. 2024 Jan 9. PMID: 38165378

Dalla Costa G, Nos C, Zabalza A, Buron M, Magyari M, Sellebjerg F, Guerrero AI, Roselli L, La Porta ML, Martinis M, Bailon R, Kontaxis S, Laporta E, Garcia E, Pokorny FB, Schuller BW, Folarin A, Stewart C, Leocani L, Vairavan S, Cummins N, Dobson R, Hotopf M, Narayan V, Montalban X, Sorensen PS, Comi G. A wearable device perspective on the standard definitions of disability progression in multiple sclerosis. Mult Scler. 2024 Jan. PMID: 38084497

Cagol A, Cortese R, Barakovic M, Schaedelin S, Ruberte E, Absinta M, Barkhof F, Calabrese M, Castellaro M, Ciccarelli O, Cocozza S, De Stefano N, Enzinger C, Filippi M, Jurynczyk M, Maggi P, Mahmoudi N, Messina S, Montalban X, Palace J, Pontillo G, Pröbstel AK, Rocca MA, Ropele S, Rovira À, Schoonheim MM, Sowa P, Strijbis E, Wattjes MP, Sormani MP, Kappos L, Granziera C, MAGNIMS Study Group. Diagnostic Performance of Cortical Lesions and the Central Vein Sign in Multiple Sclerosis. JAMA Neurol. 2024 Feb 1. PMID: 38079177

Brochet B, Solari A, Lechner-Scott J, Piehl F, Langdon D, Hupperts R, Selmaj K, Patti F, Brieva L, Maida EM, Alexandri N, Smyk A, Nolting A, Keller B, Montalban X, Kubala Havrdova E. Improvements in quality of life over 2 years with cladribine tablets in people with relapsing multiple sclerosis: The CLARIFY-MS study. Mult Scler. 2023 Dec. PMID: 37978852

Fissolo N, Benkert P, Sastre-Garriga J, Mongay-Ochoa N, Vilaseca-Jolonch A, Llufriu S, Blanco Y, Hegen H, Berek K, Perez-Miralles F, Rejdak K, Villar LM, Monreal E, Alvarez-Lafuente R, Soylu OK, Abdelhak A, Bachhuber F, Tumani H, Martínez-Yélamos S, Sánchez-López AJ, García-Merino A, Gutiérrez L, Castillo-Trivino T, Lycke J, Rosenstein I, Furlan R, Filippi M, Téllez N, Ramió-Torrentà L, Lünemann JD, Wiendl H, Eichau S, Khalil M, Kuhle J, Montalban X, Comabella M. Serum biomarker levels predict disability progression in patients with primary progressive multiple sclerosis. J Neurol Neurosurg Psychiatry. 2024 Apr 12. PMID: 37940409

Kappos L, Traboulsee A, Li DKB, Bar-Or A, Barkhof F, Montalban X, Leppert D, Baldinotti A, Schneble HM, Koendgen H, Sauter A, Wang Q, Hauser SL. Ocrelizumab exposure in relapsing-remitting multiple sclerosis: 10-year analysis of the phase 2 randomized clinical trial and its extension. J Neurol. 2024 Feb. PMID: 37906326

Domínguez-Mozo MI, González-Suárez I, Villar LM, Costa-Frossard L, Villarrubia N, Aladro Y, Pilo B, Montalbán X, Comabella M, Casanova-Peño I, Martínez-Ginés ML, García-Domínguez JM, García-Martínez MÁ, Arroyo R, Álvarez-Lafuente R. Teriflunomide and Epstein-Barr virus in a Spanish multiple sclerosis cohort: in vivo antiviral activity and clinical response. Front Immunol. 2023. PMID: 37841253

Sotirchos ES, Hu C, Smith MD, Lord HN, DuVal AL, Arrambide G, Montalban X, Akgün K, Ziemssen T, Naismith RT, Hersh CM, Hyland M, Krupp LB, Nicholas JA, Bermel RA, Mowry EM, Calabresi PA, Fitzgerald KC. Agreement Between Published Reference Resources for Neurofilament Light Chain Levels in People With Multiple Sclerosis. Neurology. 2023 Dec 4. PMID: 37816633

Coll L, Pareto D, Carbonell-Mirabent P, Cobo-Calvo Á, Arrambide G, Vidal-Jordana Á, Comabella M, Castilló J, Rodrı Guez-Acevedo B, Zabalza A, Galán I, Midaglia L, Nos C, Auger C, Alberich M, Río J, Sastre-Garriga J, Oliver A, Montalban X, Rovira À, Tintoré M, Lladó X, Tur C. Global and Regional Deep Learning Models for Multiple Sclerosis Stratification From MRI. J Magn Reson Imaging. 2024 Jul. PMID: 37803817

Graves JS, Elantkowski M, Zhang YP, Dondelinger F, Lipsmeier F, Bernasconi C, Montalban X, Midaglia L, Lindemann M. Assessment of Upper Extremity Function in Multiple Sclerosis: Feasibility of a Digital Pinching Test. JMIR Form Res. 2023 Oct 2. PMID: 37782540

Ruggieri S, Prosperini L, Al-Araji S, Annovazzi PO, Bisecco A, Ciccarelli O, De Stefano N, Filippi M, Fleischer V, Evangelou N, Enzinger C, Gallo A, Garjani A, Groppa S, Haggiag S, Khalil M, Lucchini M, Mirabella M, Montalban X, Pozzilli C, Preziosa P, Río J, Rocca MA, Rovira A, Stromillo ML, Zaffaroni M, Tortorella C, Gasperini C, MAGNIMS Study Group. Assessing treatment response to oral drugs for multiple sclerosis in real-world setting: a MAGNIMS Study. J Neurol Neurosurg Psychiatry. 2024 Jan 11. PMID: 37775266

Midaglia L, Rovira A, Miró B, Río J, Fissolo N, Castilló J, Sánchez A, Montalban X, Comabella M. Association of magnetic resonance imaging phenotypes and serum biomarker levels with treatment response and long-term disease outcomes in multiple sclerosis patients. Eur J Neurol. 2024 Jan. PMID: 37754568

Coles AJ, Achiron A, Traboulsee A, Singer BA, Pozzilli C, Oreja-Guevara C, Giovannoni G, Comi G, Freedman MS, Ziemssen T, Shiota D, Rawlings AM, Wong AT, Chirieac M, Montalban X. Safety and efficacy with alemtuzumab over 13 years in relapsing-remitting multiple sclerosis: final results from the open-label TOPAZ study. Ther Adv Neurol Disord. 2023. PMID: 37745914

Carvajal R, Tur C, Martínez-Gómez X, Bollo L, Esperalba J, Rodriguez M, Pappolla A, Cobo-Calvo A, Carbonell P, Borras-Bemejo B, Río J, Castilló J, Braga N, Mongay-Ochoa N, Rodrigo-Pendás JÁ, Vidal-Jordana Á, Arrambide G, Rodríguez-Acevedo B, Zabalza A, Midaglia L, Galán I, Comabella M, Sastre-Garriga J, Montalban X, Tintoré M, Otero-Romero S. A single-dose strategy for immunization with live attenuated vaccines is an effective option before treatment initiation in multiple sclerosis patients. Mult Scler. 2023 Dec. PMID: 37728389

Villacieros-Álvarez J, Espejo C, Arrambide G, Castillo M, Carbonell-Mirabent P, Rodriguez M, Bollo L, Castilló J, Comabella M, Galán I, Midaglia L, Mongay-Ochoa N, Nos C, Rio J, Rodríguez-Acevedo B, Sastre-Garriga J, Tur C, Vidal-Jordana A, Vilaseca A, Zabalza A, Auger C, Rovira A, Montalban X, Tintoré M, Cobo-Calvo Á. Myelin Oligodendrocyte Glycoprotein Antibodies in Adults with a First Demyelinating Event Suggestive of Multiple Sclerosis. Ann Neurol. 2023 Sep 14. PMID: 37705507

Wilson D, Chan D, Chang L, Mathis R, Verberk I, Montalban X, Comabella M, Fissolo N, Bielekova B, Masvekar R, Chitnis T, Ziemssen T, Akgün K, Blennow K, Zetterberg H, Brück W, Giovannoni G, Gnanapavan S, Bittner S, Zipp F, Comi G, Furlan R, Lehmann S, Thebault S, Freedman M, Bar-Or A, Kramer M, Otto M, Halbgebauer S, Hrusovsky K, Plavina T, Khalil M, Piehl F, Wiendl H, Kappos L, Maceski A, Willemse E, Leppert D, Teunissen C, Kuhle J. Development and multi-center validation of a fully automated digital immunoassay for neurofilament light chain: toward a clinical blood test for neuronal injury. Clin Chem Lab Med. 2024 Jan 26. PMID: 37702323

Marzo B, Vidal-Jordana A, Castilló J, Robles-Sanchez MA, Otero-Romero S, Tintore M, Montalban X, Buti M, Riveiro-Barciela M. Hepatitis B reactivation is a rare event among patients with resolved infection undergoing anti-CD20 antibodies in monotherapy without antiviral prophylaxis: results from the HEBEM study. J Neurol. 2024 Jan. PMID: 37695530

Thompson AJ, Moccia M, Amato MP, Calabresi PA, Finlayson M, Hawton A, Lublin FD, Marrie RA, Montalban X, Panzara M, Sormani MP, Strum J, Vickrey BG, Coetzee T. Do the current MS clinical course descriptors need to change and if so how? A survey of the MS community. Mult Scler. 2023 Oct. PMID: 37691493

Bar-Or A, Cross AH, Cunningham AL, Hyvert Y, Seitzinger A, Gühring H, Drouin EE, Alexandri N, Tomic D, Montalban X. Antibody response to SARS-CoV-2 vaccines in patients with relapsing multiple sclerosis treated with evobrutinib: A Bruton's tyrosine kinase inhibitor. Mult Scler. 2023 Oct. PMID: 37626477

Fissolo N, Calvo-Barreiro L, Eixarch H, Boschert U, Villar LM, Costa-Frossard L, Ferrer M, Sanchez A, Borràs E, Sabidó E, Espejo C, Montalban X, Comabella M. Molecular signature associated with cladribine treatment in patients with multiple sclerosis. Front Immunol. 2023. PMID: 37559720

Midaglia L, Felipe-Rucián A, Delgado Alvarez I, Montalban X, Tintoré M. Diagnostic challenge in children with an acquired demyelinating syndrome: an illustrative case report. Front Neurosci. 2023. PMID: 37547139

Giovannoni G, Boyko A, Correale J, Edan G, Freedman MS, Montalban X, Rammohan K, Stefoski D, Yamout B, Leist T, Aydemir A, Borsi L, di Cantogno EV. A plain language summary on assessing the long-term effectiveness of cladribine tablets in people living with relapsing multiple sclerosis: The CLASSIC-MS study. Neurodegener Dis Manag. 2023 Oct. PMID: 37535336

Robles-Sanchez MA, Moharra M, Bosch-Farré C, Hernández-Leal MJ, Montalban X, Sastre-Garriga J, Ramió-Torrentà L, Bertran-Noguer C. Views of Multiple Sclerosis Patients About Key Elements for a Decision Aid: A Qualitative Study. J Neurosci Nurs. 2023 Oct 1. PMID: 37527935

Malhotra S, Miras MCM, Pappolla A, Montalban X, Comabella M. Liquid Biopsy in Neurological Diseases. Cells. 2023 Jul 22. PMID: 37508574

Puig-Casadevall M, Álvarez-Bravo G, Varela AQ, Robles-Cedeño R, Sànchez Cirera L, Miguela A, Laguillo G, Montalban X, Hauser SL, Ramió-Torrentà L. Progressive multifocal leukoencephalopathy in a patient with relapsing multiple sclerosis treated with ocrelizumab: A case report. Eur J Neurol. 2023 Oct. PMID: 37485841

Patil SA, Joseph B, Tagliani P, Sastre-Garriga J, Montalban X, Vidal-Jordana A, Galetta SL, Balcer LJ, Kenney RC. Corrigendum to "Longitudinal stability of inter-eye differences in optical coherence tomography measures for identifying unilateral optic nerve lesions in multiple sclerosis" [Journal of the Neurological Sciences 449C (2023) Start page-End page/JOTNS D-23-00048R2]. J Neurol Sci. 2023 Oct 15. PMID: 37468371

Cobo-Calvo A, Tur C, Otero-Romero S, Carbonell-Mirabent P, Ruiz M, Pappolla A, Villacieros Alvarez J, Vidal-Jordana A, Arrambide G, Castilló J, Galan I, Rodríguez Barranco M, Midaglia LS, Nos C, Rodriguez Acevedo B, Zabalza de Torres A, Mongay N, Rio J, Comabella M, Auger C, Sastre-Garriga J, Rovira A, Tintore M, Montalban X. Association of Very Early Treatment Initiation With the Risk of Long-term Disability in Patients With a First Demyelinating Event. Neurology. 2023 Sep 26. PMID: 37468284

Gold R, Barnett M, Chan A, Feng H, Fujihara K, Giovannoni G, Montalbán X, Shi FD, Tintoré M, Xue Q, Yang C, Zhou H. Clinical use of dimethyl fumarate in multiple sclerosis treatment: an update to include China, using a modified Delphi method. Ther Adv Neurol Disord. 2023. PMID: 37465201

Fernández O, Montalban X, Agüera E, Aladro Y, Alonso A, Arroyo R, Brieva L, Calles C, Costa-Frossard L, Eichau S, García-Domínguez JM, Hernández MA, Landete L, Llaneza M, Llufriu S, Meca-Lallana JE, Meca-Lallana V, Mongay-Ochoa N, Moral E, Oreja-Guevara C, Ramió-Torrentà L, Téllez N, Romero-Pinel L, Rodríguez-Antigüedad A. [15th Post-ECTRIMS Meeting: a review of the latest developments presented at the 2022 ECTRIMS Congress (Part II)]. Rev Neurol. 2023 Jul 16. PMID: 37403243

Fernández O, Montalban X, Agüera E, Aladro Y, Alonso A, Arroyo R, Brieva L, Calles C, Costa-Frossard L, Eichau S, García-Domínguez JM, Hernández MA, Landete L, Llaneza M, Llufriu S, Meca-Lallana JE, Meca-Lallana V, Mongay-Ochoa N, Moral E, Oreja-Guevara C, Ramió-Torrentà L, Téllez N, Romero-Pinel L, Rodríguez-Antigüedad A. [15th Post-ECTRIMS Meeting: a review of the latest developments presented at the 2022 ECTRIMS Congress (Part I)]. Rev Neurol. 2023 Jul 1. PMID: 37365721

Montalban X, Wallace D, Genovese MC, Tomic D, Parsons-Rich D, Bolay CL, Kao AH, Guehring H. A plain language summary of what clinical studies can tell us about the safety of evobrutinib - a potential treatment for multiple sclerosis. Neurodegener Dis Manag. 2023 Aug. PMID: 37345645

Mongay-Ochoa N, Pareto D, Alberich M, Tintore M, Montalban X, Rovira À, Sastre-Garriga J. Validation of a New Semiautomated Segmentation Pipeline Based on the Spinal Cord Toolbox DeepSeg Algorithm to Estimate the Cervical Canal Area. AJNR Am J Neuroradiol. 2023 Jul. PMID: 37290816

Robles-Sanchez MA, Amil-Bujan P, Bosch-Farré C, Coll-Martínez C, Arévalo MJ, Anglada E, Menéndez R, Montalban X, Sastre-Garriga J, Ramió-Torrentà L, Bertran-Noguer C. An expert patient program to improve the empowerment and quality of life of people with multiple sclerosis: protocol for a multicenter pre-post intervention study. Front Neurol. 2023. PMID: 37273703

Santoyo-Medina C, Janer Cabo M, Xaudaró DF, Sanmillan GL, Sanchez Pous S, Cartaña IG, Meza Murillo ER, Sastre-Garriga J, Montalban X. Effect of Nordic Walking Training on Walking Capacity and Quality of Life for People With Multiple Sclerosis. Int J MS Care. 2023 May-Jun. PMID: 37250195

Malhotra S, Midaglia L, Chuquisana O, Patsopoulos NA, Ferrer R, Giralt M, Fissolo N, Gil-Varea E, Triviño JC, Lünemann JD, Montalban X, Comabella M. The CYP24A1 gene variant rs2762943 is associated with low serum 1,25-dihydroxyvitamin D levels in multiple sclerosis patients. Eur J Neurol. 2023 Aug. PMID: 37183562

Patil SA, Joseph B, Tagliani P, Sastre-Garriga J, Montalban X, Vidal-Jordana A, Galetta SL, Balcer LJ, Kenney RC. Longitudinal stability of inter-eye differences in optical coherence tomography measures for identifying unilateral optic nerve lesions in multiple sclerosis. J Neurol Sci. 2023 Jun 15. PMID: 37167654

Renom M, Galán I, Vidal X, Aldevert M, Curto G, Feliu P, García I, Gonzalo L, Sibera X, Anglada E, Meza R, García M, Najas V, Mongay-Ochoa N, Arévalo MJ, Vidal-Jordana Á, Tintoré M, Bascuñana H, Montalban X, Terré R, Sastre-Garriga J. Validation of the Spanish version of DYsphagia in MUltiple Sclerosis questionnaire (DYMUS). Mult Scler Relat Disord. 2023 Jun. PMID: 37086636

Giovannoni G, Boyko A, Correale J, Edan G, Freedman MS, Montalban X, Rammohan K, Stefoski D, Yamout B, Leist T, Aydemir A, Borsi L, Verdun di Cantogno E. Long-term follow-up of patients with relapsing multiple sclerosis from the CLARITY/CLARITY Extension cohort of CLASSIC-MS: An ambispective study. Mult Scler. 2023 May. PMID: 37012898

Malhotra S, Hurtado-Navarro L, Pappolla A, Villar LMM, Río J, Montalban X, Pelegrin P, Comabella M. Increased NLRP3 Inflammasome Activation and Pyroptosis in Patients With Multiple Sclerosis With Fingolimod Treatment Failure. Neurol Neuroimmunol Neuroinflamm. 2023 May. PMID: 36973075

Coll L, Pareto D, Carbonell-Mirabent P, Cobo-Calvo Á, Arrambide G, Vidal-Jordana Á, Comabella M, Castilló J, Rodríguez-Acevedo B, Zabalza A, Galán I, Midaglia L, Nos C, Salerno A, Auger C, Alberich M, Río J, Sastre-Garriga J, Oliver A, Montalban X, Rovira À, Tintoré M, Lladó X, Tur C. Deciphering multiple sclerosis disability with deep learning attention maps on clinical MRI. Neuroimage Clin. 2023. PMID: 36940621

Monreal E, Fernández-Velasco JI, García-Sánchez MI, Sainz de la Maza S, Llufriu S, Álvarez-Lafuente R, Casanova B, Comabella M, Ramió-Torrentà L, Martínez-Rodríguez JE, Brieva L, Saiz A, Eichau S, Cabrera-Maqueda JM, Villarrubia N, Espiño M, Pérez-Miralles F, Montalbán X, Tintoré M, Quiroga-Varela A, Domínguez-Mozo MI, Rodríguez-Jorge F, Chico-García JL, Lourido D, Álvarez-Cermeño JC, Masjuan J, Costa-Frossard L, Villar LM. Association of Serum Neurofilament Light Chain Levels at Disease Onset With Disability Worsening in Patients With a First Demyelinating Multiple Sclerosis Event Not Treated With High-Efficacy Drugs. JAMA Neurol. 2023 Apr 1. PMID: 36848127

Montalban X, Matthews PM, Simpson A, Petrie JL, Sammon C, Ramagopalan S, Disanto G, Kuhle J. Real-world evaluation of ocrelizumab in multiple sclerosis: A systematic review. Ann Clin Transl Neurol. 2023 Mar. PMID: 36728340

Vega E, Arrambide G, Olivé G, Castillo M, Felipe-Rucián A, Tintoré M, Montalban X, Espejo C, Sepúlveda M, Armangué T, Cobo-Calvo A. Non-ADEM encephalitis in patients with myelin oligodendrocyte glycoprotein antibodies: a systematic review. Eur J Neurol. 2023 May. PMID: 36704861

Sastre-Garriga J, Rovira A, García-Vidal A, Carbonell-Mirabent P, Alberich M, Vidal-Jordana A, Auger C, Tintore M, Montalban X, Pareto D. Spinal cord reserve in multiple sclerosis. J Neurol Neurosurg Psychiatry. 2023 Jul. PMID: 36690430

Graves JS, Ganzetti M, Dondelinger F, Lipsmeier F, Belachew S, Bernasconi C, Montalban X, van Beek J, Baker M, Gossens C, Lindemann M. Preliminary validity of the Draw a Shape Test for upper extremity assessment in multiple sclerosis. Ann Clin Transl Neurol. 2023 Feb. PMID: 36563127

Sánchez-Velasco S, Midaglia L, Vidal-Jordana A, Castillo F, Horno R, Carreras E, Serrano B, Bosch M, Agustí A, Montalban X, Tintoré M. [Esclerosis multiple. Lactancia. Lactante. Planificacion familiar. Posparto. Tratamiento modificador de la enfermedad.]. Rev Neurol. 2023 Jan 1. PMID: 36544373

Tur C, Carbonell-Mirabent P, Cobo-Calvo Á, Otero-Romero S, Arrambide G, Midaglia L, Castilló J, Vidal-Jordana Á, Rodríguez-Acevedo B, Zabalza A, Galán I, Nos C, Salerno A, Auger C, Pareto D, Comabella M, Río J, Sastre-Garriga J, Rovira À, Tintoré M, Montalban X. Association of Early Progression Independent of Relapse Activity With Long-term Disability After a First Demyelinating Event in Multiple Sclerosis. JAMA Neurol. 2023 Feb 1. PMID: 36534392

Bar-Or A, Montalban X, Hu X, Kropshofer H, Kukkaro P, Coello N, Ludwig I, Willi R, Zalesak M, Ramanathan K, Kieseier BC, Häring DA, Bagger M, Fox E. Serum Neurofilament Light Trajectories and Their Relation to Subclinical Radiological Disease Activity in Relapsing Multiple Sclerosis Patients in the APLIOS Trial. Neurol Ther. 2023 Feb. PMID: 36534274

Siddi S, Giné-Vázquez I, Bailon R, Matcham F, Lamers F, Kontaxis S, Laporta E, Garcia E, Arranz B, Dalla Costa G, Guerrero AI, Zabalza A, Buron MD, Comi G, Leocani L, Annas P, Hotopf M, Penninx BWJH, Magyari M, Sørensen PS, Montalban X, Lavelle G, Ivan A, Oetzmann C, White KM, Difrancesco S, Locatelli P, Mohr DC, Aguiló J, Narayan V, Folarin A, Dobson RJB, Dineley J, Leightley D, Cummins N, Vairavan S, Ranjan Y, Rashid Z, Rintala A, Girolamo G, Preti A, Simblett S, Wykes T, Pab Members, Myin-Germeys I, Haro JM, On Behalf Of The Radar-Cns Consortium. Biopsychosocial Response to the COVID-19 Lockdown in People with Major Depressive Disorder and Multiple Sclerosis. J Clin Med. 2022 Dec 1. PMID: 36498739

Ganzetti M, Graves JS, Holm SP, Dondelinger F, Midaglia L, Gaetano L, Craveiro L, Lipsmeier F, Bernasconi C, Montalban X, Hauser SL, Lindemann M. Neural correlates of digital measures shown by structural MRI: a post-hoc analysis of a smartphone-based remote assessment feasibility study in multiple sclerosis. J Neurol. 2023 Mar. PMID: 36469103

Sotirchos ES, Fitzgerald KC, Singh CM, Smith MD, Reyes-Mantilla M, Hersh CM, Hyland MH, Canissario R, Simmons SB, Arrambide G, Montalban X, Comabella M, Naismith RT, Qiao M, Krupp LB, Nicholas JA, Akgün K, Ziemssen T, Rudick R, Fisher E, Bermel RA, Mowry EM, Calabresi PA. Associations of sNfL with clinico-radiological measures in a large MS population. Ann Clin Transl Neurol. 2023 Jan. PMID: 36427295

Filippi M, Preziosa P, Arnold DL, Barkhof F, Harrison DM, Maggi P, Mainero C, Montalban X, Sechi E, Weinshenker BG, Rocca MA. Present and future of the diagnostic work-up of multiple sclerosis: the imaging perspective. J Neurol. 2023 Mar. PMID: 36427168

Montalban X, Wallace D, Genovese MC, Tomic D, Parsons-Rich D, Le Bolay C, Kao AH, Guehring H. Characterisation of the safety profile of evobrutinib in over 1000 patients from phase II clinical trials in multiple sclerosis, rheumatoid arthritis and systemic lupus erythematosus: an integrated safety analysis. J Neurol Neurosurg Psychiatry. 2023 Jan. PMID: 36418156

Wiendl H, Schmierer K, Hodgkinson S, Derfuss T, Chan A, Sellebjerg F, Achiron A, Montalban X, Prat A, De Stefano N, Barkhof F, Leocani L, Vermersch P, Chudecka A, Mwape C, Holmberg KH, Boschert U, Roy S, MAGNIFY-MS Study Group. Specific Patterns of Immune Cell Dynamics May Explain the Early Onset and Prolonged Efficacy of Cladribine Tablets: A MAGNIFY-MS Substudy. Neurol Neuroimmunol Neuroinflamm. 2023 Jan. PMID: 36411081

Fissolo N, Pappolla A, Rio J, Villar LM, Perez-Hoyos S, Sanchez A, Gutierrez L, Montalban X, Comabella M. Serum Levels of CXCL13 Are Associated With Teriflunomide Response in Patients With Multiple Sclerosis. Neurol Neuroimmunol Neuroinflamm. 2023 Jan. PMID: 36411079

Kuhlmann T, Moccia M, Coetzee T, Cohen JA, Correale J, Graves J, Marrie RA, Montalban X, Yong VW, Thompson AJ, Reich DS, International Advisory Committee on Clinical Trials in Multiple Sclerosis. Multiple sclerosis progression: time for a new mechanism-driven framework. Lancet Neurol. 2023 Jan. PMID: 36410373

Comabella M, Tintore M, Sao Avilés A, Carbonell-Mirabent P, Malhotra S, Rovira A, Fissolo N, Lünemann JD, Montalban X. Increased cytomegalovirus immune responses at disease onset are protective in the long-term prognosis of patients with multiple sclerosis. J Neurol Neurosurg Psychiatry. 2023 Mar. PMID: 36344261

Rotstein D, Solomon JM, Sormani MP, Montalban X, Ye XY, Dababneh D, Muccilli A, Saab G, Shah P. Association of NEDA-4 With No Long-term Disability Progression in Multiple Sclerosis and Comparison With NEDA-3: A Systematic Review and Meta-analysis. Neurol Neuroimmunol Neuroinflamm. 2022 Nov. PMID: 36224046

Martí-Juan G, Frías M, Garcia-Vidal A, Vidal-Jordana A, Alberich M, Calderon W, Piella G, Camara O, Montalban X, Sastre-Garriga J, Rovira À, Pareto D. Detection of lesions in the optic nerve with magnetic resonance imaging using a 3D convolutional neural network. Neuroimage Clin. 2022. PMID: 36126515

Meaton I, Altokhis A, Allen CM, Clarke MA, Sinnecker T, Meier D, Enzinger C, Calabrese M, De Stefano N, Pitiot A, Giorgio A, Schoonheim MM, Paul F, Pawlak MA, Schmidt R, Granziera C, Kappos L, Montalban X, Rovira À, Wuerfel J, Evangelou N. Paramagnetic rims are a promising diagnostic imaging biomarker in multiple sclerosis. Mult Scler. 2022 Dec. PMID: 36017870

Cree BA, Selmaj KW, Steinman L, Comi G, Bar-Or A, Arnold DL, Hartung HP, Montalbán X, Havrdová EK, Sheffield JK, Minton N, Cheng CY, Silva D, Kappos L, Cohen JA. Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Up to 5 years of follow-up in the DAYBREAK open-label extension trial. Mult Scler. 2022 Oct. PMID: 35765217

Arrambide G, Espejo C, Carbonell-Mirabent P, Dieli-Crimi R, Rodríguez-Barranco M, Castillo M, Auger C, Cárdenas-Robledo S, Castilló J, Cobo-Calvo Á, Galán I, Midaglia L, Nos C, Otero-Romero S, Río J, Rodríguez-Acevedo B, Ruiz-Ortiz M, Salerno A, Tagliani P, Tur C, Vidal-Jordana A, Zabalza A, Sastre-Garriga J, Rovira A, Comabella M, Hernández-González M, Montalban X, Tintore M. The kappa free light chain index and oligoclonal bands have a similar role in the McDonald criteria. Brain. 2022 Nov 21. PMID: 35727945

de Stefano N, Barkhof F, Montalban X, Achiron A, Derfuss T, Chan A, Hodgkinson S, Prat A, Leocani L, Schmierer K, Sellebjerg F, Vermersch P, Wiendl H, Keller B, Roy S, MAGNIFY-MS Study Group. Early Reduction of MRI Activity During 6 Months of Treatment With Cladribine Tablets for Highly Active Relapsing Multiple Sclerosis: MAGNIFY-MS. Neurol Neuroimmunol Neuroinflamm. 2022 Jul. PMID: 35701185

Zabalza A, Thompson AJ, Montalban X. Two years of COVID-19 in the MS community: What have we learnt so far? Mult Scler. 2022 Jun. PMID: 35549532

Matute-Blanch C, Brito V, Midaglia L, Villar LM, Garcia-Diaz Barriga G, Guzman de la Fuente A, Borrás E, Fernández-García S, Calvo-Barreiro L, Miguez A, Costa-Frossard L, Pinteac R, Sabidó E, Alberch J, Fitzgerald DC, Montalban X, Comabella M. Inflammation in multiple sclerosis induces a specific reactive astrocyte state driving non-cell-autonomous neuronal damage. Clin Transl Med. 2022 May. PMID: 35538884